{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:10:41Z","timestamp":1792120241059,"version":"4.4.0"},"reference-count":248,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Rep"],"DOI":"10.3892\/or.2023.8496","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T03:08:07Z","timestamp":1675998487000},"source":"Crossref","is-referenced-by-count":93,"title":["Modulating epigenetic modifications for cancer therapy (Review)"],"prefix":"10.3892","volume":"49","author":[{"given":"Leonardo","family":"Castro\u2011Mu\u00f1oz","sequence":"first","affiliation":[{"name":"The Wistar Institute, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena\u00e9","family":"Ulloa","sequence":"additional","affiliation":[{"name":"Faculty of Science and Engineering\/Cell Biology, University of Turku and \u00c5bo Akademi University, Turku 20500, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Sahlgren","sequence":"additional","affiliation":[{"name":"Faculty of Science and Engineering\/Cell Biology, University of Turku and \u00c5bo Akademi University, Turku 20500, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Lizano","sequence":"additional","affiliation":[{"name":"Unidad de Investigacion Biomedica en Cancer, Instituto Nacional de Cancerolog\u00eda-Universidad Nacional Autonoma de Mexico, Ciudad de Mexico 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"De La Cruz-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Laboratory of Research in Metabolic and Infectious Diseases, Multidisciplinary Academic Division of Comalcalco, Juarez Autonomous University of Tabasco, Comalcalco, Tabasco 86650, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Contreras\u2011Paredes","sequence":"additional","affiliation":[{"name":"Unidad de Investigacion Biomedica en Cancer, Instituto Nacional de Cancerolog\u00eda-Universidad Nacional Autonoma de Mexico, Ciudad de Mexico 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"key20230308125116_b1-or-49-3-08496","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20230308125116_b2-or-49-3-08496","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","article-title":"Mutant p53 as a guardian of the cancer cell","volume":"26","author":"Mantovani","year":"2019","journal-title":"Cell Death Differ"},{"key":"key20230308125116_b3-or-49-3-08496","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1534\/genetics.114.173492","article-title":"What do you mean, \u2018epigenetic\u2019?","volume":"199","author":"Deans","year":"2015","journal-title":"Genetics"},{"key":"key20230308125116_b4-or-49-3-08496","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.gene.2019.04.025","article-title":"The Yin and Yang of cancer genes","volume":"704","author":"Bashyam","year":"2019","journal-title":"Gene"},{"key":"key20230308125116_b5-or-49-3-08496","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-biophys-062920-063639","article-title":"Structures and functions of chromatin fibers","volume":"50","author":"Chen","year":"2021","journal-title":"Annu Rev Biophys"},{"key":"key20230308125116_b6-or-49-3-08496","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10555-017-9715-8","article-title":"Non-coding RNAs, epigenetics, and cancer: Tying it all together","volume":"37","author":"Ferreira","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"key20230308125116_b7-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-981-15-3449-2_1","article-title":"Epigenetics in health and disease","volume":"1253","author":"Zhang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"key20230308125116_b8-or-49-3-08496","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: The potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol Cancer"},{"key":"key20230308125116_b9-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1053\/j.gastro.2019.09.005","article-title":"Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas","volume":"157","author":"Ding","year":"2019","journal-title":"Gastroenterology"},{"key":"key20230308125116_b10-or-49-3-08496","doi-asserted-by":"publisher","first-page":"R144","DOI":"10.1186\/gb-2013-14-12-r144","article-title":"Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition","volume":"14","author":"Malouf","year":"2013","journal-title":"Genome Biol"},{"key":"key20230308125116_b11-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"key":"key20230308125116_b12-or-49-3-08496","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat Rev Genet"},{"key":"key20230308125116_b13-or-49-3-08496","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/genes9120620","article-title":"Structural basis of DNMT1 and DNMT3A-mediated DNA methylation","volume":"9","author":"Ren","year":"2018","journal-title":"Genes (Basel)"},{"key":"key20230308125116_b14-or-49-3-08496","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-biochem-103019-102815","article-title":"Role of mammalian DNA methyltransferases in development","volume":"89","author":"Chen","year":"2020","journal-title":"Annu Rev Biochem"},{"key":"key20230308125116_b15-or-49-3-08496","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrg3354","article-title":"DNA methylation: Roles in mammalian development","volume":"14","author":"Smith","year":"2013","journal-title":"Nat Rev Genet"},{"key":"key20230308125116_b16-or-49-3-08496","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25477","article-title":"Structural basis for DNMT3A-mediated de novo DNA methylation","volume":"554","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"key20230308125116_b17-or-49-3-08496","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/nar\/gky947","article-title":"DNMT3L facilitates DNA methylation partly by maintaining DNMT3A stability in mouse embryonic stem cells","volume":"47","author":"Veland","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b18-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/genes11111336","article-title":"DNMTs and impact of CpG content, transcription factors, consensus motifs, lncRNAs, and histone marks on DNA methylation","volume":"11","author":"Loaeza-Loaeza","year":"2020","journal-title":"Genes (Basel)"},{"key":"key20230308125116_b19-or-49-3-08496","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13059-021-02384-1","article-title":"Roles of TET and TDG in DNA demethylation in proliferating and non-proliferating immune cells","volume":"22","author":"Onodera","year":"2021","journal-title":"Genome Biol"},{"key":"key20230308125116_b20-or-49-3-08496","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev"},{"key":"key20230308125116_b21-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e69476","DOI":"10.7554\/eLife.69476","article-title":"Epigenetic reprogramming by TET enzymes impacts co-transcriptional R-loops","volume":"11","author":"Sabino","year":"2022","journal-title":"Elife"},{"key":"key20230308125116_b22-or-49-3-08496","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41421-018-0039-9","article-title":"DNA methylation reprogramming of functional elements during mammalian embryonic development","volume":"4","author":"Li","year":"2018","journal-title":"Cell Discov"},{"key":"key20230308125116_b23-or-49-3-08496","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41586-020-1974-9","article-title":"SPEN integrates transcriptional and epigenetic control of X-inactivation","volume":"578","author":"Dossin","year":"2020","journal-title":"Nature"},{"key":"key20230308125116_b24-or-49-3-08496","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.cell.2019.01.043","article-title":"Genomic imprinting and physiological processes in mammals","volume":"176","author":"Tucci","year":"2019","journal-title":"Cell"},{"key":"key20230308125116_b25-or-49-3-08496","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omto.2021.09.006","article-title":"DNA-methylation-induced silencing of DIO3OS drives non-small cell lung cancer progression via activating hnRNPK-MYC-CDC25A axis","volume":"23","author":"Zhang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"key20230308125116_b26-or-49-3-08496","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12864-018-4842-3","article-title":"An integrated-omics analysis of the epigenetic landscape of gene expression in human blood cells","volume":"19","author":"Kennedy","year":"2018","journal-title":"BMC Genomics"},{"key":"key20230308125116_b27-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-1804-1_1","article-title":"Cancer epigenetics: An introduction","volume":"1238","author":"Kanwal","year":"2015","journal-title":"Methods Mol Biol"},{"key":"key20230308125116_b28-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-15-3278","article-title":"DNA methylation in cancer and aging","volume":"76","author":"Klutstein","year":"2016","journal-title":"Cancer Res"},{"key":"key20230308125116_b29-or-49-3-08496","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/1940-6207.CAPR-15-0349","article-title":"DNA hypomethylation contributes to genomic instability and intestinal cancer initiation","volume":"9","author":"Sheaffer","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"key20230308125116_b30-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00018-010-0624-z","article-title":"Epigenetic aberrations during oncogenesis","volume":"68","author":"Hatziapostolou","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"key20230308125116_b31-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4161\/epi.29025","article-title":"Key tumor suppressor genes inactivated by \u2018greater promoter\u2019 methylation and somatic mutations in head and neck cancer","volume":"9","author":"Guerrero-Preston","year":"2014","journal-title":"Epigenetics"},{"key":"key20230308125116_b32-or-49-3-08496","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000516122","article-title":"RAP1GAP functions as a tumor suppressor gene and is regulated by DNA methylation in differentiated thyroid cancer","volume":"161","author":"Faam","year":"2021","journal-title":"Cytogenet Genome Res"},{"key":"key20230308125116_b33-or-49-3-08496","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.humpath.2021.11.008","article-title":"Genetic and methylation status of CDKN2A (p14ARF\/p16INK4A) and TP53 genes in recurrent respiratory papillomatosis","volume":"119","author":"Chantre-Justino","year":"2022","journal-title":"Hum Pathol"},{"key":"key20230308125116_b34-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e0230524","DOI":"10.1371\/journal.pone.0230524","article-title":"DNA methylation biomarkers for nasopharyngeal carcinoma","volume":"15","author":"Han","year":"2020","journal-title":"PLoS One"},{"key":"key20230308125116_b35-or-49-3-08496","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","article-title":"DNA methyltransferases in hematological malignancies","volume":"47","author":"Hoang","year":"2020","journal-title":"J Genet Genomics"},{"key":"key20230308125116_b36-or-49-3-08496","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/sj.bjc.6604932","article-title":"Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo","volume":"100","author":"Steele","year":"2009","journal-title":"Br J Cancer"},{"key":"key20230308125116_b37-or-49-3-08496","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1038\/s41467-020-19704-x","article-title":"EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy","volume":"11","author":"Bao","year":"2020","journal-title":"Nat Commun"},{"key":"key20230308125116_b38-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s13346-018-0556-y","article-title":"Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells","volume":"8","author":"Vijayaraghavalu","year":"2018","journal-title":"Drug Deliv Transl Res"},{"key":"key20230308125116_b39-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.2174\/1568026619666181120150122","article-title":"DNA methyltransferase inhibitors and their therapeutic potential","volume":"18","author":"Zhou","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"key20230308125116_b40-or-49-3-08496","doi-asserted-by":"publisher","first-page":"18357","DOI":"10.1002\/jcb.29147","article-title":"Quercetin modifies 5\u2032CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells","volume":"120","author":"Kedhari Sundaram","year":"2019","journal-title":"J Cell Biochem"},{"key":"key20230308125116_b41-or-49-3-08496","doi-asserted-by":"crossref","first-page":"183","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-3.15113","article-title":"Effect of valproic acid and zebularine on SOCS-1 and SOCS-3 gene expression in colon carcinoma SW48 cell line","volume":"42","author":"Sanaei","year":"2020","journal-title":"Exp Oncol"},{"key":"key20230308125116_b42-or-49-3-08496","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1078-0432.CCR-19-1266","article-title":"Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas","volume":"26","author":"Capdevila","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20230308125116_b43-or-49-3-08496","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fphar.2018.00366","article-title":"Targeting DNA methyltranferases in urological tumors","volume":"9","author":"Marques-Magalh\u00e3es","year":"2018","journal-title":"Front Pharmacol"},{"key":"key20230308125116_b44-or-49-3-08496","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/biom6030037","article-title":"An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer","volume":"6","author":"Xylinas","year":"2016","journal-title":"Biomolecules"},{"key":"key20230308125116_b45-or-49-3-08496","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"key20230308125116_b46-or-49-3-08496","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/13543776.2016.1203419","article-title":"Therapeutic effects of EGCG: A patent review","volume":"26","author":"Chakrawarti","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"key20230308125116_b47-or-49-3-08496","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/jm00200a012","article-title":"Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine","volume":"21","author":"Beisler","year":"1978","journal-title":"J Med Chem"},{"key":"key20230308125116_b48-or-49-3-08496","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1124\/dmd.117.079400","article-title":"Identification of structural and molecular features involved in the transport of 3\u2032-Deoxy-nucleoside analogs by human equilibrative nucleoside transporter 3","volume":"46","author":"Rahman","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"key20230308125116_b49-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/0006-2952(79)90454-4","article-title":"Kinetics of phosphorylation of 5-aza-2\u2032-deoxyycytidine by deoxycytidine kinase","volume":"28","author":"Momparler","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"key20230308125116_b50-or-49-3-08496","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0092-8674(83)90327-6","article-title":"On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs","volume":"33","author":"Santi","year":"1983","journal-title":"Cell"},{"key":"key20230308125116_b51-or-49-3-08496","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/03602532.2018.1437446","article-title":"Effects of 5-Aza-2\u2032-deoxycytidine (decitabine) on gene expression","volume":"50","author":"Seelan","year":"2018","journal-title":"Drug Metab Rev"},{"key":"key20230308125116_b52-or-49-3-08496","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1096\/fj.11-190025","article-title":"5-Aza-2\u2032-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins","volume":"26","author":"Zheng","year":"2012","journal-title":"FASEB J"},{"key":"key20230308125116_b53-or-49-3-08496","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF02135399","article-title":"5-Azacytidine, a new, highly effective cancerostatic","volume":"20","author":"Sorm","year":"1964","journal-title":"Experientia"},{"key":"key20230308125116_b54-or-49-3-08496","first-page":"123","article-title":"The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice","volume":"11","author":"Sorm","year":"1964","journal-title":"Neoplasma"},{"key":"key20230308125116_b55-or-49-3-08496","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000225641","article-title":"5-azacytidine in refractory acute leukemia","volume":"39","author":"Case","year":"1982","journal-title":"Oncology"},{"key":"key20230308125116_b56-or-49-3-08496","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0092-8674(83)90179-4","article-title":"Developmental activation of the H-2K gene is correlated with an increase in DNA methylation","volume":"35","author":"Tanaka","year":"1983","journal-title":"Cell"},{"key":"key20230308125116_b57-or-49-3-08496","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood.V48.3.331.331","article-title":"5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia","volume":"48","author":"Vogler","year":"1976","journal-title":"Blood"},{"key":"key20230308125116_b58-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","article-title":"Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes","volume":"11","author":"Kaminskas","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20230308125116_b59-or-49-3-08496","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","article-title":"The timeline of epigenetic drug discovery: From reality to dreams","volume":"11","author":"Ganesan","year":"2019","journal-title":"Clin Epigenetics"},{"key":"key20230308125116_b60-or-49-3-08496","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","article-title":"Clinical update on hypomethylating agents","volume":"110","author":"Duchmann","year":"2019","journal-title":"Int J Hematol"},{"key":"key20230308125116_b61-or-49-3-08496","doi-asserted-by":"publisher","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","article-title":"Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines","volume":"69","author":"Schaefer","year":"2009","journal-title":"Cancer Res"},{"key":"key20230308125116_b62-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"key":"key20230308125116_b63-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/1535-7163.MCT-13-0137","article-title":"Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2\u2032-deoxycytidine in solid tumor cells","volume":"12","author":"Venturelli","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"key20230308125116_b64-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20230308125116_b65-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.4161\/cc.7.14.6268","article-title":"A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts","volume":"7","author":"Fabre","year":"2008","journal-title":"Cell Cycle"},{"key":"key20230308125116_b66-or-49-3-08496","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12958-021-00790-5","article-title":"5-aza-2\u2032-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt\/\u03b2-catenin pathway in human uterine leiomyomas","volume":"19","author":"Carbajo-Garc\u00eda","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"key20230308125116_b67-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3390\/cancers13102357","article-title":"Pre-operative decitabine in colon cancer patients: Analyses on WNT target methylation and expression","volume":"13","author":"Linnekamp","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20230308125116_b68-or-49-3-08496","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","article-title":"How I treat MDS after hypomethylating agent failure","volume":"133","author":"Santini","year":"2019","journal-title":"Blood"},{"key":"key20230308125116_b69-or-49-3-08496","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2007-06-093948","article-title":"Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin","volume":"111","author":"Mabaera","year":"2008","journal-title":"Blood"},{"key":"key20230308125116_b70-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3892\/ijo.2015.2894","article-title":"The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2\u2032 deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo","volume":"46","author":"Susanto","year":"2015","journal-title":"Int J Oncol"},{"key":"key20230308125116_b71-or-49-3-08496","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1042\/CS20150697","article-title":"Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis","volume":"130","author":"Evans","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"key20230308125116_b72-or-49-3-08496","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat Rev Genet"},{"key":"key20230308125116_b73-or-49-3-08496","first-page":"1221","article-title":"Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells","volume":"22","author":"Meng","year":"2009","journal-title":"Oncol Rep"},{"key":"key20230308125116_b74-or-49-3-08496","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/onc.2008.377","article-title":"Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells","volume":"28","author":"Lee","year":"2009","journal-title":"Oncogene"},{"key":"key20230308125116_b75-or-49-3-08496","first-page":"6456","article-title":"Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2\u2032-deoxycytidine","volume":"62","author":"Nguyen","year":"2002","journal-title":"Cancer Res"},{"key":"key20230308125116_b76-or-49-3-08496","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-1-4419-9967-2_13","article-title":"Epigenetic therapies in MDS and AML","volume":"754","author":"Griffiths","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"key20230308125116_b77-or-49-3-08496","first-page":"119","article-title":"Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines","volume":"1","author":"Nguyen","year":"2010","journal-title":"Lung Cancer (Auckl)"},{"key":"key20230308125116_b78-or-49-3-08496"},{"key":"key20230308125116_b79-or-49-3-08496","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1006\/jmbi.1998.2491","article-title":"Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone","volume":"286","author":"Hurd","year":"1999","journal-title":"J Mol Biol"},{"key":"key20230308125116_b80-or-49-3-08496","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1042\/BST0320910","article-title":"Zebularine: A new drug for epigenetic therapy","volume":"32","author":"Yoo","year":"2004","journal-title":"Biochem Soc Trans"},{"key":"key20230308125116_b81-or-49-3-08496","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/156800911794328510","article-title":"Epigenetic regulation of gene expression as an anticancer drug target","volume":"11","author":"Ferguson","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"key20230308125116_b82-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1517\/17425255.2014.947263","article-title":"Hydralazine-valproate: A repositioned drug combination for the epigenetic therapy of cancer","volume":"10","author":"Due\u00f1as-Gonzalez","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20230308125116_b83-or-49-3-08496","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/cmdc.200900017","article-title":"Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1","volume":"4","author":"Singh","year":"2009","journal-title":"ChemMedChem"},{"key":"key20230308125116_b84-or-49-3-08496","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/13543784.2019.1667331","article-title":"Guadecitabine (SGI-110): An investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"28","author":"Daher-Reyes","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"key20230308125116_b85-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2174\/138945012802008973","article-title":"Discovery and mechanism of natural products as modulators of histone acetylation","volume":"13","author":"Salvador","year":"2012","journal-title":"Curr Drug Targets"},{"key":"key20230308125116_b86-or-49-3-08496","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.biopha.2014.12.016","article-title":"Green tea polyphenol EGCG reverse cisplatin resistance of A549\/DDP cell line through candidate genes demethylation","volume":"69","author":"Zhang","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"key20230308125116_b87-or-49-3-08496","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13223-018-0259-4","article-title":"Histone modifications and their role in epigenetics of atopy and allergic diseases","volume":"14","author":"Alaskhar Alhamwe","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"key20230308125116_b88-or-49-3-08496","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","article-title":"Lateral thinking: How histone modifications regulate gene expression","volume":"32","author":"Lawrence","year":"2016","journal-title":"Trends Genet"},{"key":"key20230308125116_b89-or-49-3-08496","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"Lakshmaiah","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"key20230308125116_b90-or-49-3-08496","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/cbic.201000438","article-title":"KAT(ching) metabolism by the tail: Insight into the links between lysine acetyltransferases and metabolism","volume":"12","author":"Albaugh","year":"2011","journal-title":"Chembiochem"},{"key":"key20230308125116_b91-or-49-3-08496","doi-asserted-by":"publisher","first-page":"972312","DOI":"10.3389\/fendo.2022.972312","article-title":"The role of protein acetylation in carcinogenesis and targeted drug discovery","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20230308125116_b92-or-49-3-08496","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/1947601911417176","article-title":"Histone modifiers in cancer: Friends or foes?","volume":"2","author":"Cohen","year":"2011","journal-title":"Genes Cancer"},{"key":"key20230308125116_b93-or-49-3-08496","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-019-1044-z","article-title":"Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer","volume":"38","author":"Fan","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20230308125116_b94-or-49-3-08496","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2015.00108","article-title":"The role of histone acetyltransferases in normal and malignant hematopoiesis","volume":"5","author":"Sun","year":"2015","journal-title":"Front Oncol"},{"key":"key20230308125116_b95-or-49-3-08496","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-020-01182-w","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"key20230308125116_b96-or-49-3-08496","doi-asserted-by":"publisher","first-page":"10325","DOI":"10.1038\/s41598-020-70622-w","article-title":"Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia","volume":"10","author":"Carraway","year":"2020","journal-title":"Sci Rep"},{"key":"key20230308125116_b97-or-49-3-08496","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-020-01783-9","article-title":"HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer","volume":"39","author":"Hu","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"key20230308125116_b98-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/cells10051001","article-title":"Broad-spectrum HDAC inhibitors promote autophagy through FOXO transcription factors in neuroblastoma","volume":"10","author":"K\u00f6rholz","year":"2021","journal-title":"Cells"},{"key":"key20230308125116_b99-or-49-3-08496","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch Pharm Res"},{"key":"key20230308125116_b100-or-49-3-08496","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s11064-016-2110-y","article-title":"Sirtuins and their roles in brain aging and neurodegenerative disorders","volume":"42","author":"J\u0119\u015bko","year":"2017","journal-title":"Neurochem Res"},{"key":"key20230308125116_b101-or-49-3-08496","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.exger.2009.10.001","article-title":"Role of HDAC1 in senescence, aging, and cancer","volume":"45","author":"Willis-Martinez","year":"2010","journal-title":"Exp Gerontol"},{"key":"key20230308125116_b102-or-49-3-08496","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"key20230308125116_b103-or-49-3-08496","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20230308125116_b104-or-49-3-08496","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1093\/nar\/gkx224","article-title":"Molecular basis for the methylation specificity of ATXR5 for histone H3","volume":"45","author":"Bergamin","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b105-or-49-3-08496","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cell.2012.03.025","article-title":"SnapShot: Histone lysine methylase complexes","volume":"149","author":"Mohan","year":"2012","journal-title":"Cell"},{"key":"key20230308125116_b106-or-49-3-08496","first-page":"612","article-title":"Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke","volume":"13","author":"From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR)","year":"2018","journal-title":"Int J Stroke"},{"key":"key20230308125116_b107-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.01.002","article-title":"Targeting histone lysine methylation in cancer","volume":"150","author":"McGrath","year":"2015","journal-title":"Pharmacol Ther"},{"key":"key20230308125116_b108-or-49-3-08496","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s40495-018-0141-6","article-title":"Histone H3 mutations in cancer","volume":"4","author":"Wan","year":"2018","journal-title":"Curr Pharmacol Rep"},{"key":"key20230308125116_b109-or-49-3-08496","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1158\/1541-7786.MCR-14-0389","article-title":"Histone methyltransferase hSETD1A is a novel regulator of metastasis in breast cancer","volume":"13","author":"Salz","year":"2015","journal-title":"Mol Cancer Res"},{"key":"key20230308125116_b110-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"key":"key20230308125116_b111-or-49-3-08496","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng.3757","article-title":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","volume":"49","author":"Papillon-Cavanagh","year":"2017","journal-title":"Nat Genet"},{"key":"key20230308125116_b112-or-49-3-08496","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13148-021-01098-2","article-title":"Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy","volume":"13","author":"Yang","year":"2021","journal-title":"Clin Epigenetics"},{"key":"key20230308125116_b113-or-49-3-08496","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N Engl J Med"},{"key":"key20230308125116_b114-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1124\/mol.112.079624","article-title":"Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway","volume":"82","author":"Yaseen","year":"2012","journal-title":"Mol Pharmacol"},{"key":"key20230308125116_b115-or-49-3-08496","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-an overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J Dermatol"},{"key":"key20230308125116_b116-or-49-3-08496","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br J Cancer"},{"key":"key20230308125116_b117-or-49-3-08496","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key20230308125116_b118-or-49-3-08496","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J Hematol Oncol"},{"key":"key20230308125116_b119-or-49-3-08496","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/excr.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor","volume":"241","author":"Nakajima","year":"1998","journal-title":"Exp Cell Res"},{"key":"key20230308125116_b120-or-49-3-08496","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"key20230308125116_b121-or-49-3-08496","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1359-4117.2002.01039.x","article-title":"A phase I trial of depsipeptide (FR901228) in patients with advanced cancer","volume":"2","author":"Marshall","year":"2002","journal-title":"J Exp Ther Oncol"},{"key":"key20230308125116_b122-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3109\/10428194.2016.1160082","article-title":"Use of class I histone deacetylase inhibitor romidepsin in combination regimens","volume":"57","author":"Petrich","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"key20230308125116_b123-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20230308125116_b124-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40265-014-0270-0","article-title":"Belinostat: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"key20230308125116_b125-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/cancers11101530","article-title":"Epigenetic drugs for cancer and microRNAs: A focus on histone deacetylase inhibitors","volume":"11","author":"Autin","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20230308125116_b126-or-49-3-08496","first-page":"1093","article-title":"Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines","volume":"31","author":"Spratlin","year":"2011","journal-title":"Anticancer Res"},{"key":"key20230308125116_b127-or-49-3-08496","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/CCO.0b013e3283127095","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"20","author":"Lee","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"key20230308125116_b128-or-49-3-08496","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/hdy.2010.54","article-title":"Epigenetics and gene expression","volume":"105","author":"Gibney","year":"2010","journal-title":"Heredity (Edinb)"},{"key":"key20230308125116_b129-or-49-3-08496","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.canlet.2017.03.027","article-title":"Circular RNAs and cancer","volume":"396","author":"He","year":"2017","journal-title":"Cancer Lett"},{"key":"key20230308125116_b130-or-49-3-08496","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4161\/rna.7.4.12746","article-title":"Regulation of alternative splicing by short non-coding nuclear RNAs","volume":"7","author":"Khanna","year":"2010","journal-title":"RNA Biol"},{"key":"key20230308125116_b131-or-49-3-08496","first-page":"800","article-title":"U1 snRNA associates with TFIIH and regulates transcriptional initiation","volume":"9","author":"Kwek","year":"2002","journal-title":"Nat Struct Mol Biol"},{"key":"key20230308125116_b132-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/nar\/gkq1153","article-title":"7SK small nuclear RNA directly affects HMGA1 function in transcription regulation","volume":"39","author":"Eilebrecht","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b133-or-49-3-08496","doi-asserted-by":"publisher","first-page":"D162","DOI":"10.1093\/nar\/gkl994","article-title":"Noncoding RNAs database (ncRNAdb)","volume":"35","author":"Szymanski","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b134-or-49-3-08496","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcp.21230","article-title":"Small RNAs: Regulators and guardians of the genome","volume":"213","author":"Chu","year":"2007","journal-title":"J Cell Physiol"},{"key":"key20230308125116_b135-or-49-3-08496","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41417-019-0130-x","article-title":"Circular RNAs: Epigenetic regulators in cancerous and noncancerous skin diseases","volume":"27","author":"Abi","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"key20230308125116_b136-or-49-3-08496","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrg.2015.10","article-title":"Unique features of long non-coding RNA biogenesis and function","volume":"17","author":"Quinn","year":"2016","journal-title":"Nat Rev Genet"},{"key":"key20230308125116_b137-or-49-3-08496","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/2211-5463.12397","article-title":"Profiling expression of coding genes, long noncoding RNA, and circular RNA in lung adenocarcinoma by ribosomal RNA-depleted RNA sequencing","volume":"8","author":"Ding","year":"2018","journal-title":"FEBS Open Bio"},{"key":"key20230308125116_b138-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"key20230308125116_b139-or-49-3-08496","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"key":"key20230308125116_b140-or-49-3-08496","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nrm1644","article-title":"MicroRNA biogenesis: Coordinated cropping and dicing","volume":"6","author":"Kim","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20230308125116_b141-or-49-3-08496","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","article-title":"MicroRNA genes are transcribed by RNA polymerase II","volume":"23","author":"Lee","year":"2004","journal-title":"EMBO J"},{"key":"key20230308125116_b142-or-49-3-08496","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1101\/gad.1284105","article-title":"Perspective: Machines for RNAi","volume":"19","author":"Tomari","year":"2005","journal-title":"Genes Dev"},{"key":"key20230308125116_b143-or-49-3-08496","doi-asserted-by":"publisher","first-page":"643657","DOI":"10.3389\/fmolb.2021.643657","article-title":"A glimpse of \u2018dicer biology\u2019 through the structural and functional perspective","volume":"8","author":"Paturi","year":"2021","journal-title":"Front Mol Biosci"},{"key":"key20230308125116_b144-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1039\/C8SC00010G","article-title":"Exploring PAZ\/3\u2032-overhang interaction to improve siRNA specificity. A combined experimental and modeling study","volume":"9","author":"Alagia","year":"2018","journal-title":"Chem Sci"},{"key":"key20230308125116_b145-or-49-3-08496","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1073\/pnas.0510928103","article-title":"MicroRNAs direct rapid deadenylation of mRNA","volume":"103","author":"Wu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20230308125116_b146-or-49-3-08496","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4161\/epi.20706","article-title":"Naturally occurring endo-siRNA silences LINE-1 retrotransposons in human cells through DNA methylation","volume":"7","author":"Chen","year":"2012","journal-title":"Epigenetics"},{"key":"key20230308125116_b147-or-49-3-08496","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10555-020-09863-0","article-title":"piRNAs: Biogenesis and their potential roles in cancer","volume":"39","author":"Guo","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"key20230308125116_b148-or-49-3-08496","article-title":"piRNAs-guardians of the germline","author":"Sparmann","year":"2019","journal-title":"Nat Res"},{"key":"key20230308125116_b149-or-49-3-08496","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-biochem-060614-034258","article-title":"PIWI-interacting RNA: Its biogenesis and functions","volume":"84","author":"Iwasaki","year":"2015","journal-title":"Annu Rev Biochem"},{"key":"key20230308125116_b150-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/jid.2010.63","article-title":"MicroRNA expression profiles associated with mutational status and survival in malignant melanoma","volume":"130","author":"Caramuta","year":"2010","journal-title":"J Invest Dermatol"},{"key":"key20230308125116_b151-or-49-3-08496","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1745-6150-6-23","article-title":"MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival","volume":"6","author":"Chi","year":"2011","journal-title":"Biol Direct"},{"key":"key20230308125116_b152-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1073\/pnas.0800135105","article-title":"Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin","volume":"105","author":"Garzon","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20230308125116_b153-or-49-3-08496","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","article-title":"MicroRNA gene expression deregulation in human breast cancer","volume":"65","author":"Iorio","year":"2005","journal-title":"Cancer Res"},{"key":"key20230308125116_b154-or-49-3-08496","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20230308125116_b155-or-49-3-08496","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20230308125116_b156-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/cdd.2013.125","article-title":"The miR-17\/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease","volume":"20","author":"Mogilyansky","year":"2013","journal-title":"Cell Death Differ"},{"key":"key20230308125116_b157-or-49-3-08496","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"key20230308125116_b158-or-49-3-08496","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jmcb\/mju018","article-title":"New insights into p53 functions through its target microRNAs","volume":"6","author":"Liao","year":"2014","journal-title":"J Mol Cell Biol"},{"key":"key20230308125116_b159-or-49-3-08496","doi-asserted-by":"publisher","first-page":"695723","DOI":"10.3389\/fcell.2021.695723","article-title":"Regulation of miRNAs expression by mutant p53 gain of function in cancer","volume":"9","author":"Madrigal","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20230308125116_b160-or-49-3-08496","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/cancers10070213","article-title":"Human oncoviruses and p53 tumor suppressor pathway deregulation at the origin of human cancers","volume":"10","author":"Tornesello","year":"2018","journal-title":"Cancers (Basel)"},{"key":"key20230308125116_b161-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b162-or-49-3-08496","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-021-00330-4","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20230308125116_b163-or-49-3-08496","doi-asserted-by":"publisher","first-page":"598817","DOI":"10.3389\/fonc.2020.598817","article-title":"Long non-coding RNAs: The regulatory mechanisms, research strategies, and future directions in cancers","volume":"10","author":"Gao","year":"2020","journal-title":"Front Oncol"},{"key":"key20230308125116_b164-or-49-3-08496","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gpb.2015.09.006","article-title":"Roles, functions, and mechanisms of long non-coding RNAs in cancer","volume":"14","author":"Fang","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"key20230308125116_b165-or-49-3-08496","doi-asserted-by":"publisher","first-page":"12375","DOI":"10.1074\/jbc.R116.760884","article-title":"Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses","volume":"292","author":"Mathy","year":"2017","journal-title":"J Biol Chem"},{"key":"key20230308125116_b166-or-49-3-08496","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang","year":"2011","journal-title":"Mol Cell"},{"key":"key20230308125116_b167-or-49-3-08496","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13578-020-00445-9","article-title":"An update on long intergenic noncoding RNA p21: A regulatory molecule with various significant functions in cancer","volume":"10","author":"Amirinejad","year":"2020","journal-title":"Cell Biosci"},{"key":"key20230308125116_b168-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e1700","DOI":"10.1038\/cddis.2015.67","article-title":"Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes","volume":"6","author":"Hall","year":"2015","journal-title":"Cell Death Dis"},{"key":"key20230308125116_b169-or-49-3-08496","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","article-title":"A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response","volume":"142","author":"Huarte","year":"2010","journal-title":"Cell"},{"key":"key20230308125116_b170-or-49-3-08496","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3389\/fonc.2019.00920","article-title":"The emerging role of major regulatory RNAs in cancer control","volume":"9","author":"Dai","year":"2019","journal-title":"Front Oncol"},{"key":"key20230308125116_b171-or-49-3-08496","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tibs.2017.12.001","article-title":"Paraspeckles: Where long noncoding RNA meets phase separation","volume":"43","author":"Fox","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"key20230308125116_b172-or-49-3-08496","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/2159-8290.CD-15-0921","article-title":"LncRNA GClnc1 promotes gastric carcinogenesis and may Act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern","volume":"6","author":"Sun","year":"2016","journal-title":"Cancer Discov"},{"key":"key20230308125116_b173-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.ymthe.2019.09.001","article-title":"ncRNA-encoded peptides or proteins and cancer","volume":"27","author":"Wang","year":"2019","journal-title":"Mol Ther"},{"key":"key20230308125116_b174-or-49-3-08496","doi-asserted-by":"publisher","first-page":"622294","DOI":"10.3389\/fonc.2020.622294","article-title":"LncRNA-encoded peptide: Functions and predicting methods","volume":"10","author":"Xing","year":"2021","journal-title":"Front Oncol"},{"key":"key20230308125116_b175-or-49-3-08496","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2020.04.006","article-title":"Translatable circRNAs and lncRNAs: Driving mechanisms and functions of their translation products","volume":"483","author":"Kong","year":"2020","journal-title":"Cancer Lett"},{"key":"key20230308125116_b176-or-49-3-08496","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2017.09.015","article-title":"A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth","volume":"68","author":"Huang","year":"2017","journal-title":"Mol Cell"},{"key":"key20230308125116_b177-or-49-3-08496","doi-asserted-by":"publisher","first-page":"777374","DOI":"10.3389\/fonc.2021.777374","article-title":"Functional peptides encoded by long non-coding RNAs in gastrointestinal cancer","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"key20230308125116_b178-or-49-3-08496","doi-asserted-by":"publisher","first-page":"12322","DOI":"10.1038\/s41598-019-48774-1","article-title":"Harnessing the tissue and plasma lncRNA-peptidome to discover peptide-based cancer biomarkers","volume":"9","author":"Chakraborty","year":"2019","journal-title":"Sci Rep"},{"key":"key20230308125116_b179-or-49-3-08496","doi-asserted-by":"publisher","first-page":"194410","DOI":"10.1016\/j.bbagrm.2019.194410","article-title":"Pre-mRNA structures forming circular RNAs","volume":"1862","author":"Welden","year":"2019","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"key20230308125116_b180-or-49-3-08496","first-page":"41","article-title":"Circular RNA splicing","volume-title":"Circular RNAs. Advances in Experimental Medicine and Biology","author":"Eger","year":"2018"},{"key":"key20230308125116_b181-or-49-3-08496","doi-asserted-by":"publisher","first-page":"617281","DOI":"10.3389\/fcell.2021.617281","article-title":"Insights into the role of CircRNAs: Biogenesis, characterization, functional, and clinical impact in human malignancies","volume":"9","author":"Nisar","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20230308125116_b182-or-49-3-08496","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-015-0259-0","article-title":"MicroRNA-7: A promising new target in cancer therapy","volume":"15","author":"Zhao","year":"2015","journal-title":"Cancer Cell Int"},{"key":"key20230308125116_b183-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.4143\/crt.2017.537","article-title":"Circular RNA-ZFR inhibited cell proliferation and promoted apoptosis in gastric cancer by sponging miR-130a\/miR-107 and modulating PTEN","volume":"50","author":"Liu","year":"2018","journal-title":"Cancer Res Treat"},{"key":"key20230308125116_b184-or-49-3-08496","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12929-019-0523-z","article-title":"The emerging roles and functions of circular RNAs and their generation","volume":"26","author":"Yu","year":"2019","journal-title":"J Biomed Sci"},{"key":"key20230308125116_b185-or-49-3-08496","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.7150\/jca.58182","article-title":"The emerging role of the interactions between circular RNAs and RNA-binding proteins in common human cancers","volume":"12","author":"Jiang","year":"2021","journal-title":"J Cancer"},{"key":"key20230308125116_b186-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.7150\/thno.42174","article-title":"Circular RNA-protein interactions: Functions, mechanisms, and identification","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"key20230308125116_b187-or-49-3-08496","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/s41388-018-0369-y","article-title":"A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy","volume":"37","author":"Du","year":"2018","journal-title":"Oncogene"},{"key":"key20230308125116_b188-or-49-3-08496","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcancer.2020.09.002","article-title":"Non-coding RNAs, guardians of the p53 galaxy","volume":"75","author":"Chen","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"key20230308125116_b189-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1093\/nar\/gkw027","article-title":"Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2","volume":"44","author":"Du","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b190-or-49-3-08496","doi-asserted-by":"publisher","first-page":"8085","DOI":"10.2147\/OTT.S215823","article-title":"Circular RNA circ-Foxo3 induced cell apoptosis in urothelial carcinoma via interaction with miR-191-5p","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"key20230308125116_b191-or-49-3-08496","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/jnci\/djx166","article-title":"Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis","volume":"110","author":"Yang","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"key20230308125116_b192-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","article-title":"mRNA vaccines for COVID-19: What, why and how","volume":"17","author":"Park","year":"2021","journal-title":"Int J Biol Sci"},{"key":"key20230308125116_b193-or-49-3-08496","doi-asserted-by":"publisher","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"key20230308125116_b194-or-49-3-08496","doi-asserted-by":"publisher","first-page":"612393","DOI":"10.3389\/fmed.2020.612393","article-title":"Long non-coding RNAs in cancer: Implications for diagnosis, prognosis, and therapy","volume":"7","author":"Qian","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"key20230308125116_b195-or-49-3-08496","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/onc.2017.361","article-title":"Circular RNAs in cancer: Opportunities and challenges in the field","volume":"37","author":"Kristensen","year":"2018","journal-title":"Oncogene"},{"key":"key20230308125116_b196-or-49-3-08496","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-3-319-42059-2_12","article-title":"Non-coding RNAs: Therapeutic strategies and delivery systems","volume":"937","author":"Ling","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"key20230308125116_b197-or-49-3-08496","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1093\/nar\/gkw139","article-title":"Transcriptional gene silencing in humans","volume":"44","author":"Weinberg","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"key20230308125116_b198-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1002\/wrna.1640","article-title":"Artificial miRNAs as therapeutic tools: Challenges and opportunities","volume":"12","author":"Kotowska-Zimmer","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"key20230308125116_b199-or-49-3-08496","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2144\/000113442","article-title":"Controlling transcription with noncoding RNAs in mammalian cells","volume":"48","author":"Turner","year":"2010","journal-title":"Biotechniques"},{"key":"key20230308125116_b200-or-49-3-08496","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2174\/1389201019666180528084059","article-title":"Therapeutic potential of small activating RNAs (saRNAs) in human cancers","volume":"19","author":"Yoon","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"key20230308125116_b201-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: A primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol Genet"},{"key":"key20230308125116_b202-or-49-3-08496","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/B978-0-12-813679-9.00002-6","article-title":"RNA-based applications in diagnostic and therapeutics for cancer","volume-title":"Advances in Cell and Molecular Diagnostics","author":"Raghavendra","year":"2018"},{"key":"key20230308125116_b203-or-49-3-08496","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","article-title":"MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: First steps from bench to bedside","volume":"15","author":"Ratti","year":"2020","journal-title":"Targ Oncol"},{"key":"key20230308125116_b204-or-49-3-08496","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ncrna.2019.09.001","article-title":"Current role of non-coding RNAs in the clinical setting","volume":"4","author":"Vicentini","year":"2019","journal-title":"Noncoding RNA Res"},{"key":"key20230308125116_b205-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.3390\/ijms21093252","article-title":"Aptamers and antisense oligonucleotides for diagnosis and treatment of hematological diseases","volume":"21","author":"Giudice","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20230308125116_b206-or-49-3-08496","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-0716-0771-8_3","article-title":"Knocking down long noncoding RNAs using antisense oligonucleotide gapmers","volume":"2176","author":"Maruyama","year":"2020","journal-title":"Methods Mol Biol"},{"key":"key20230308125116_b207-or-49-3-08496","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jsbmb.2014.02.002","article-title":"Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo","volume":"141","author":"Bhan","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20230308125116_b208-or-49-3-08496","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/1389557515666150324123208","article-title":"MicroRNA therapeutics: The next magic bullet?","volume":"15","author":"Simonson","year":"2015","journal-title":"Mini Rev Med Chem"},{"key":"key20230308125116_b209-or-49-3-08496","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-018-0827-8","article-title":"Circular RNAs function as ceRNAs to regulate and control human cancer progression","volume":"17","author":"Zhong","year":"2018","journal-title":"Mol Cancer"},{"key":"key20230308125116_b210-or-49-3-08496","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nmeth1079","article-title":"MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells","volume":"4","author":"Ebert","year":"2007","journal-title":"Nat Methods"},{"key":"key20230308125116_b211-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4161\/psb.21299","article-title":"RNA decoys: An emerging component of plant regulatory networks?","volume":"7","author":"Banks","year":"2012","journal-title":"Plant Signal Behav"},{"key":"key20230308125116_b212-or-49-3-08496","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: Progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"key20230308125116_b213-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.4155\/fmc.15.107","article-title":"miRNA therapeutics: A new class of drugs with potential therapeutic applications in the heart","volume":"7","author":"Bernardo","year":"2015","journal-title":"Future Med Chem"},{"key":"key20230308125116_b214-or-49-3-08496","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4939-6588-5_3","article-title":"Generation of efficient miRNA inhibitors using tough decoy constructs","volume-title":"Cardiac Gene Therapy. Methods in Molecular Biology","author":"Yoo","year":"2017"},{"key":"key20230308125116_b215-or-49-3-08496","doi-asserted-by":"publisher","first-page":"710738","DOI":"10.3389\/fmolb.2021.710738","article-title":"RNA therapeutics-research and clinical advancements","volume":"8","author":"Feng","year":"2021","journal-title":"Front Mol Biosci"},{"key":"key20230308125116_b216-or-49-3-08496","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"key20230308125116_b217-or-49-3-08496","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"key20230308125116_b218-or-49-3-08496","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"key20230308125116_b219-or-49-3-08496","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat Biotechnol"},{"key":"key20230308125116_b220-or-49-3-08496","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J Control Release"},{"key":"key20230308125116_b221-or-49-3-08496","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2133\/dmpk.22.142","article-title":"Targeted delivery systems of small interfering RNA by systemic administration","volume":"22","author":"Kawakami","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"key20230308125116_b222-or-49-3-08496","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35051606","article-title":"Inactivation of the apoptosis effector Apaf-1 in malignant melanoma","volume":"409","author":"Soengas","year":"2001","journal-title":"Nature"},{"key":"key20230308125116_b223-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"key20230308125116_b224-or-49-3-08496","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20230308125116_b225-or-49-3-08496","first-page":"296","article-title":"Panobinostat (Farydak): A novel option for the treatment of relapsed or relapsed and refractory multiple myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"P T"},{"key":"key20230308125116_b226-or-49-3-08496","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14728222.2018.1535594","article-title":"Let-7 microRNA as a potential therapeutic target with implications for immunotherapy","volume":"22","author":"Gilles","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"key20230308125116_b227-or-49-3-08496","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.omtn.2019.11.008","article-title":"Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo","volume":"19","author":"Segal","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"key20230308125116_b228-or-49-3-08496","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3892\/ol.2014.2706","article-title":"MicroRNA let-7g and let-7i inhibit hepatoma cell growth concurrently via downregulation of the anti-apoptotic protein B-cell lymphoma-extra large","volume":"9","author":"Wu","year":"2015","journal-title":"Oncol Lett"},{"key":"key20230308125116_b229-or-49-3-08496","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12935-021-01797-z","article-title":"MicroRNA-1182 and let-7a exert synergistic inhibition on invasion, migration and autophagy of cholangiocarcinoma cells through down-regulation of NUAK1","volume":"21","author":"Pan","year":"2021","journal-title":"Cancer Cell Int"},{"key":"key20230308125116_b230-or-49-3-08496","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1166\/mex.2021.2001","article-title":"MicroRNA-7 agomir is a potential bioactive material for breast cancer therapy by inhibiting breast cancer stem cell tumorigenicity","volume":"11","author":"Li","year":"2021","journal-title":"Mater Express"},{"key":"key20230308125116_b231-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"key20230308125116_b232-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20230308125116_b233-or-49-3-08496","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s13104-017-2930-0","article-title":"The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection","volume":"10","author":"Winata","year":"2017","journal-title":"BMC Res Notes"},{"key":"key20230308125116_b234-or-49-3-08496","doi-asserted-by":"publisher","first-page":"6810","DOI":"10.3390\/ijms22136810","article-title":"Long Noncoding RNA GAS5 in breast cancer: Epigenetic mechanisms and biological functions","volume":"22","author":"Filippova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20230308125116_b235-or-49-3-08496","doi-asserted-by":"publisher","first-page":"S564","DOI":"10.21037\/tcr.2016.09.04","article-title":"Long non-coding RNAs: New opportunities and old challenges in cancer therapy","volume":"5","author":"Williams","year":"2016","journal-title":"Transl Cancer Res"},{"key":"key20230308125116_b236-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1533033821990074","DOI":"10.1177\/1533033821990074","article-title":"Upregulation of long noncoding RNA_GAS5 suppresses cell proliferation and metastasis in laryngeal cancer via regulating PI3K\/AKT\/mTOR signaling pathway","volume":"20","author":"Liu","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"key20230308125116_b237-or-49-3-08496","first-page":"607","article-title":"BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers","volume":"12","author":"Smaldone","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"key20230308125116_b238-or-49-3-08496","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1038\/s41388-018-0665-6","article-title":"Mechanisms involved in the activation of C\/EBP\u03b1 by small activating RNA in hepatocellular carcinoma","volume":"38","author":"Zhao","year":"2019","journal-title":"Oncogene"},{"key":"key20230308125116_b239-or-49-3-08496","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/hep.26669","article-title":"Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo","volume":"59","author":"Reebye","year":"2014","journal-title":"Hepatology"},{"key":"key20230308125116_b240-or-49-3-08496","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br J Haematol"},{"key":"key20230308125116_b241-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2174\/0929866525666171123213148","article-title":"The role of Grb2 in cancer and peptides as Grb2 antagonists","volume":"24","author":"Ijaz","year":"2018","journal-title":"Protein Pept Lett"},{"key":"key20230308125116_b242-or-49-3-08496","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: A single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol"},{"key":"key20230308125116_b243-or-49-3-08496","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"key20230308125116_b244-or-49-3-08496","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"key20230308125116_b245-or-49-3-08496","doi-asserted-by":"publisher","first-page":"13044","DOI":"10.1021\/jacs.1c02248","article-title":"Repro-gramming of protein-targeted small-molecule medicines to RNA by ribonuclease recruitment","volume":"143","author":"Zhang","year":"2021","journal-title":"J Am Chem Soc"},{"key":"key20230308125116_b246-or-49-3-08496","article-title":"Drug-like small molecules that inhibit expression of the oncogenic microRNA-21","author":"Shortridge","journal-title":"bioRxiv"},{"key":"key20230308125116_b247-or-49-3-08496","doi-asserted-by":"publisher","first-page":"13242","DOI":"10.1002\/anie.201808823","article-title":"Discovery of small molecule ligands for MALAT1 by tuning an RNA-binding scaffold","volume":"57","author":"Donlic","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"key20230308125116_b248-or-49-3-08496","doi-asserted-by":"publisher","first-page":"188502","DOI":"10.1016\/j.bbcan.2021.188502","article-title":"Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer","volume":"1875","author":"Goyal","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Oncology Reports"],"original-title":[],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:40:58Z","timestamp":1701862858000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/or.2023.8496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":248,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,10]]}},"URL":"https:\/\/doi.org\/10.3892\/or.2023.8496","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"article-number":"59"}}